Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 74Radiotherapy 34Carboplatin 21Bevacizumab 18Magnetic Resonance Spectroscopy 17Irinotecan 16Carmustine 16Vincristine 14Surgical Procedures, Operative 13Filgrastim 13Procarbazine 10Erlotinib Hydrochloride 8Cyclophosphamide 8Peripheral Blood Stem Cell Transplantation 7O(6)-benzylguanine 7Lomustine 7Etoposide 7sargramostim 6Imatinib Mesylate 6Flucytosine 6Cisplatin 62-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 6temsirolimus 5Vorinostat 5Thiotepa 5Radiotherapy, Intensity-Modulated 5Radiation 5Immunohistochemistry 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × fluarix × Clear all
NCT02747407 2021-10-29

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Wake Forest University Health Sciences

Completed
55 enrolled
CNS

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡